Jinkyun Kim

Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then.